Accelerated recovery from acute hypoxia in obese mice is due to obesity-associated up-regulation of interleukin-1 receptor antagonist

Endocrinology

Volumn 150, Issue 6, 2009, Pages 2660-2667

  Sherry, Christina L ^a   Kim, Stephanie S ^a   Freund, Gregory G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HYPOXIA; IMMUNOMODULATION; LIPID DIET; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN INDUCTION; WHITE ADIPOSE TISSUE;

ACUTE DISEASE; ADIPOSE TISSUE, WHITE; ANIMALS; ANOXIA; DIETARY FATS; DISEASE MODELS, ANIMAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OBESITY; RECEPTORS, INTERLEUKIN-1; RECOVERY OF FUNCTION; UP-REGULATION;

EID: 66649087134     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1622     Document Type: Article

References (61)

1. Lago F, Dieguez C, Gómez-Reino J, Gualillo O 2007 Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 3:716-724
2. Kershaw EE, Flier JS 2004 Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556
3. Hauner H 2005 Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 64:163-169 (Pubitemid 40813538)
4. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW 2004 Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273-2282
5. Meliga E, Strem BM, Duckers HJ, Serruys PW 2007 Adipose-derived cells. Cell Transplant 16:963-970
6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
7. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumié A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clément K 2005 Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54:2277-2286
8. Gordon S, Taylor PR 2005 Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:953-964
9. Gordon S 2003 Alternative activation of macrophages. Nat Rev Immunol 3:23-35 (Pubitemid 37328697)
10. Martinez FO, Sica A, Mantovani A, Locati M 2008 Macrophage activation and polarization. Front Biosci 13:453-461
11. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR 2007 Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56:16-23
12. Odegaard JI, Chawla A 2008 Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 4:619-626
13. Bourlier V, Zakaroff-Girard A, Miranville A, De Barros S, Maumus M, Sengenes C, Galitzky J, Lafontan M, Karpe F, Frayn KN, Bouloumié A 2008 Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117:806-815
14. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, Zlabinger GJ, Stulnig TM 2007 Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 31:1420-1428
15. Guest CB, Gao Y, O'Conner JC, Freund GG 2007 Obesity and Immunity. In: Ader R, ed. Pyschoneuroimmunology. 4th ed. San Diego: Elsevier; 993-1012
16. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM 2002 IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87:1184-1188
17. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, Rohner-Jeanrenaud F, Burger D, Dayer JM, Meier CA 2003 Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52:1104-1110
18. Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C, Juge-Aubry CE, Dayer JM, Nicklin MJ, Meda P, Rohner-Jeanrenaud F, Meier CA 2006 Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 49:387-393
19. Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, Vannice JL 1992 Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA 89:9117-9120
20. Perrier S, Darakhshan F, Hajduch E 2006 IL-1 receptor antagonist in metabolic diseases: Dr. Jekyll or Mr. Hyde? FEBS Lett 580:6289-6294
21. García MC, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O, Horn M, Ahrén B, Enerback S, Ohlsson C, Wallenius V, Jansson JO 2006 Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 55:1205-1213
22. Chida D, Osaka T, Hashimoto O, Iwakura Y 2006 Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes 55:971-977
23. Matsuki T, Horai R, Sudo K, Iwakura Y 2003 IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 198:877-888
24. Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM, Nicklin MJ, Meier CA 2005 Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 54:3503-3509
25. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH 2001 The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38:789-795
26. Hall JA, French TK, Rasmusson KD, Vesty JC, Roberts CA, Rimmasch HL, Kfoury AG, Renlund DG 2005 The paradox of obesity in patients with heart failure. J Am Acad Nurse Pract 17:542-546
27. Galal W, van Domburg RT, Feringa HH, Schouten O, Elhendy A, Bax JJ, Awara AM, Klein J, Poldermans D 2007 Relation of body mass index to outcome in patients with known or suspected coronary artery disease. Am J Cardiol 99:1485-1490
28. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ 2007 Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 120:863-870
29. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB 2005 Survival advantages of obesity in dialysis patients. Am J Clin Nutr 81:543-554
30. Escalante A, Haas RW, del Rincón I 2005 Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624-1629
31. Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE 2004 Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50:3450-3457
32. Waugh J, Perry CM 2005 Anakinra: a review of its use in the management of rheumatoid arthritis. Biodrugs 19:189-202
33. Johnson DR, O'Connor JC, Hartman ME, Tapping RI, Freund GG 2007 Acute hypoxia activates the neuroimmune system which diabetes exacerbates. J Neurosci 27:1161-1166
34. Sherry CL, Kramer JM, York JM, Freund GG 2009 Behavioral recovery from acute hypoxia is reliant on leptin. Brain Behav Immun 23:169-175
35. Sherry CL, O'Connor JC, Kramer JM, Freund GG 2007 Augmented lipopolysaccharide-induced TNF-α production by peritoneal macrophages in type 2 diabetic mice is dependent on elevated glucose and requires p38 Map kinase. J Immunol 178:663-670
36. Carr D, Friedman MA 2005 Is obesity stigmatizing? Body weight, perceived discrimination, and psychological well-being in the United States. J Health Soc Behav 46:244-259
37. Habbu A, Lakkis NM, Dokainish H 2006 The obesity paradox: fact or fiction? Am J Cardiol 98:944-948
38. Anker SD, Steinborn W, Strassburg S 2004 Cardiac cachexia. Ann Med 36:518-529
39. Weindruch R, Walford RL, Fligiel S, Guthrie D 1986 The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr 116:641-654
40. Gajjar A, Kubo C, Johnson BC, Good RA 1987 Influence of extremes of protein and energy intake on survival of B/W mice. J Nutr 117:1136-1140
41. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, Nguyen T, Martin CK, Volaufova J, Most MM, Greenway FL, Smith SR, Deutsch WA, Williamson DA, Ravussin E, Pennington CALERIE Team 2006 Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295:1539-1548
42. Shanley DP, Kirkwood TB 2006 Caloric restriction does not enhance longevity in all species and is unlikely to do so in humans. Biogerontology 7:165-168
43. Keller HH 2004 Nutrition and health-related quality of life in frail older adults. J Nutr Health Aging 8:245-252 (Pubitemid 39044740)
44. Bales CW, Buhr G 2008 Is obesity bad for older persons? A systematic review of the pros and cons of weight reduction in later life. J Am Med Dir Assoc 9:302-312
45. Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP, Cardiovascular Study Research Group 2001 Weight change in old age and its association with mortality. J Am Geriatr Soc 49:1309-1318
46. Centers for Disease Control and Prevention 2008 WISQARS leading causes of death. Atlanta: Centers for Disease Control and Prevention
47. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G 2001 Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751
48. O'Rourke RW, Kay T, Lyle EA, Traxler SA, Deveney CW, Jobe BA, Roberts Jr CT, Marks D, Rosenbaum JT 2006 Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol 146:39-46
49. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF 2003 Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817
50. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB 2004 Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 65:634-651, quiz 730
51. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ 2008 Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 63:652-657
52. Moraes RC, Blondet A, Birkenkamp-Demtroeder K, Tirard J, Orntoft TF, Gertler A, Durand P, Naville D, Bégeot M 2003 Study of the alteration of gene expression in adipose tissue of diet-induced obese mice by microarray and reverse transcription-polymerase chain reaction analyses. Endocrinology 144:4773-4782
53. Lin S, Thomas TC, Storlien LH, Huang XF 2000 Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 24:639-646
54. Gabay C, Dreyer M, Pellegrinelli N, Chicheportiche R, Meier CA 2001 Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J Clin Endocrinol Metab 86:783-791
55. Dreyer MG, Juge-Aubry CE, Gabay C, Lang U, Rohner-Jeanrenaud F, Dayer JM, Meier CA 2003 Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor κB/PU. 1 binding site. Biochem J 370:591-599
56. Banks AS, Davis SM, Bates SH, Myers Jr MG 2000 Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 275:14563-14572
57. Mantovani A, Muzio M, Ghezzi P, Colotta F, Introna M 1996 Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor. Int J Clin Lab Res 26:7-14
58. Johnson DR, Sherry CL, York JM, Freund GG 2008 Acute hypoxia, diabetes, and neuroimmune dysregulation: converging mechanisms in the brain. Neuroscientist 14:235-239
59. Rothwell N 2003 Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immunol 17:152-157 (Pubitemid 36434364)
60. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA 2003 Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 140:471-476
61. Giordano FJ 2005 Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115:500-508 (Pubitemid 40322219)